Whiss P A, Lundahl T H, Bengtsson T, Lindahl T L, Lunell E, Larsson R
Division of Pharmacology, Faculty of Health Sciences, Linköping, SE-581 85, Sweden.
Toxicol Appl Pharmacol. 2000 Mar 1;163(2):95-104. doi: 10.1006/taap.1999.8853.
The role of platelets in cardiovascular disease associated with smoking is becoming more established, but the effects of nicotine on platelets are unclear. Nicotine therapy is used for smoking cessation in both health and disease. Consequently, the effects of nicotine on platelets are of particular significance in disorders such as renal disease, which is associated with defective platelet function, increased cardiovascular morbidity, and altered nicotine metabolism. Thus, the aim of the present study was to investigate the acute effects of nicotine infusion (NI) on platelets in seven healthy subjects (HS) and seven patients with renal failure (RF). All subjects were nicotine users and had refrained from using nicotine for 36 h before NI. Blood was collected before, immediately after, and 2 h after NI. The plasma concentrations of nicotine and its main metabolite cotinine were determined by gas chromatography. Platelet responsiveness was assessed by aggregometry and flow cytometry in whole blood (P-selectin surface expression, fibrinogen- and von Willebrand factor-binding), P-selectin expression in isolated platelets, and immunoassays of platelet release (beta-thromboglobulin, platelet factor 4, and soluble P-selectin) and nitric oxide (NO) products. The plasma levels of cotinine, but not nicotine, were significantly higher in RF compared to HS at all time points. In both groups, collagen-induced platelet aggregation was restrained immediately after NI, when the plasma concentration of nicotine was maximal, and was restored after 2 h. Two hours after NI, activation-dependent P-selectin surface expression in isolated platelets increased in both groups. This increased platelet responsiveness occurred simultaneously with a significant increase of plasma cotinine and a decrease of NO products. Thus, the present study suggests that nicotine, directly or through some secondary mechanism or metabolite, only slightly potentiates some of the platelet responses. Renal failure appears not to influence the effects of nicotine on platelets.
血小板在与吸烟相关的心血管疾病中的作用日益明确,但尼古丁对血小板的影响尚不清楚。尼古丁疗法用于健康人群和患病者的戒烟。因此,尼古丁对血小板的影响在诸如肾病等疾病中具有特殊意义,肾病与血小板功能缺陷、心血管发病率增加以及尼古丁代谢改变有关。因此,本研究的目的是调查尼古丁输注(NI)对7名健康受试者(HS)和7名肾衰竭患者(RF)血小板的急性影响。所有受试者均为尼古丁使用者,在NI前36小时未使用尼古丁。在NI前、NI后即刻以及NI后2小时采集血液。通过气相色谱法测定血浆中尼古丁及其主要代谢产物可替宁的浓度。通过全血凝集测定法和流式细胞术(P-选择素表面表达、纤维蛋白原和血管性血友病因子结合)、分离血小板中P-选择素的表达以及血小板释放(β-血小板球蛋白、血小板因子4和可溶性P-选择素)和一氧化氮(NO)产物的免疫测定来评估血小板反应性。在所有时间点,RF组中可替宁的血浆水平均显著高于HS组,但尼古丁的血浆水平并非如此。在两组中,当血浆尼古丁浓度达到最大值时,NI后即刻胶原诱导的血小板聚集受到抑制,2小时后恢复。NI后2小时,两组中分离血小板中激活依赖性P-选择素表面表达均增加。血小板反应性的这种增加与血浆可替宁的显著增加和NO产物的减少同时发生。因此,本研究表明,尼古丁直接或通过某些次要机制或代谢产物,仅轻微增强了某些血小板反应。肾衰竭似乎不影响尼古丁对血小板的作用。